SCHEMBL31246118

SCHEMBL31246118

COc1ncccc1OC(=O)N1CCNCC1

nearest known ligand 0.47

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
HTR1A P08908 2/20 0.43
SLC6A2 P23975 2/20 0.43
ALDH1A1 P00352 3/20 0.42
KDM4E B2RXH2 3/20 0.42
HSD17B10 Q99714 2/20 0.42
MEN1 O00255 1/20 0.42
MAPT P10636 1/20 0.42
KMT2A Q03164 1/20 0.42
CHRNB4 P30926 2/20 0.41
CHRNA3 P32297 2/20 0.41
SLC6A4 P31645 1/20 0.41
SLC6A3 Q01959 1/20 0.41
GAA P10253 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
TP53 P04637 1/20 0.41
HPGD P15428 1/20 0.40
TSHR P16473 1/20 0.40
REN P00797 4/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23851238 1.00 HTR1A (0.43) HTR1ASLC6A2ALDH1A1KDM4EHSD17B10
SCHEMBL22978732 0.86 ALDH1A1 (0.55) ALDH1A1KDM4EHSD17B10MEN1MAPT
SCHEMBL23851281 0.82 KDM4E (0.44) ALDH1A1KDM4EHSD17B10MEN1MAPT
SCHEMBL28386256 0.81 TRPV1 (0.42) HTR1ASLC6A2ALDH1A1KDM4EHSD17B10
SCHEMBL14740641 0.80 TP53 (0.55) ALDH1A1MEN1MAPTKMT2AGAA
SCHEMBL25314260 0.78 CFTR (0.36) ALDH1A1SLC6A4GAASMN1; SMN2TP53
SCHEMBL30930984 0.78 ALDH1A1 (0.41) ALDH1A1KDM4EHSD17B10MEN1MAPT
SCHEMBL28938505 0.78 REN (0.39) HTR1ASLC6A2ALDH1A1MEN1KMT2A
SCHEMBL27508507 0.78 ALDH1A1 (0.54) ALDH1A1KDM4EHSD17B10MEN1MAPT
SCHEMBL1434922 0.75 TRPV1 (0.54) HTR1ASLC6A2SLC6A4SLC6A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024238793-A1 FUSED TRIAZINONES FOR USE IN THE TREATMENT OF CANCER RGENTA THERAPEUTICS, INC. (US) 2024-11-21 WO disclosed